$1,347.11
Value $1.27T
LLY and ZVRA stock compared: price, dividend, valuation and results, from SEC filings.
$1,347.11
Value $1.27T
$8.76
Value $514M
Eli Lilly and Company (LLY) has a market value of $1.27T and Zevra Therapeutics (ZVRA) $514M. Over the last year, with dividends, LLY moved +29.1% and ZVRA -9.5%. The P/E is 46.1 for LLY and 6.7 for ZVRA. Dividend yield: LLY 0.47%, ZVRA none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LLY$1.27T
ZVRA$514M
LLY is 2,471 times ZVRA
Revenue, 12 months
LLY$86.5B
ZVRA$148M
LLY is 585 times ZVRA
Net income, 12 months
LLY$27.6B
ZVRA$78M
LLY is 354 times ZVRA
Operating margin
LLY–
ZVRA60.8%
ROIC
LLY35.5%
ZVRA36.3%
0.8 points apart
P/E
LLY46.1
ZVRA6.7
LLY is 6.8 times ZVRA
Dividend yield
LLY0.5%
ZVRA0.0%
0.5 points apart
5-year return
LLY+439.5%
ZVRA+4.3%
435.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LLY+439.5%
ZVRA+4.3%
| Period | LLYWith dividends | ZVRAWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | +29.1%Price +28.3% | -9.5%Price -9.5% |
| 3 years since November 20, 2023 | +130.0%+32.0% a yearPrice +125.4% | +95.5%+25.0% a yearPrice +95.5% |
| 5 years since November 19, 2021 | +439.5%+40.1% a yearPrice +416.7% | +4.3%+0.8% a yearPrice +4.3% |
| 10 years since November 21, 2016 | +1,944.6%+35.2% a yearPrice +1,657.7% | -86.6%-18.2% a yearPrice -86.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LLYEli Lilly and CompanyZVRAZevra Therapeutics
| Price | $1,347.11 | $8.76 |
|---|---|---|
| Market value | $1.27T | $514M |
| Enterprise value (EV) | $1.32T | $319M |
| P/E | 46.1 | 6.7 |
| P/E, 5-year median | 49.9 | – |
| P/B | 31.6 | 2.2 |
| EV/EBIT | 37.8 | 3.6 |
| Free cash flow yield | 1.6% | 7.4% |
| Revenue, 12 months | $86.5B | $148M |
|---|---|---|
| Net income, 12 months | $27.6B | $78M |
| Free cash flow, 12 months | $19.7B | $38M |
| Earnings per share, 12 months | $30.81 | $1.19 |
| Revenue growth, year on year | 44.7% | 350.9% |
| Revenue growth a year, past | +21.6%over 5 years | +51.6%over 5 years |
| EPS growth a year, past | +27.6%over 5 years | – |
| Gross margin | 83.6% | 95.4% |
|---|---|---|
| Operating margin | – | 60.8% |
| Net margin | 31.9% | 52.8% |
| ROIC | 35.5% | 36.3% |
| ROE | 88.6% | 41.1% |
| Cash | $4.9B | $196M |
|---|---|---|
| Total debt | $49.5B | $1.2M |
| Net debt / EBITDA | 1.2 | -2.1 |
| Interest cover | 38.9× | 24.6× |
| Dividend yield | 0.5% | – |
|---|---|---|
| Dividend per share, 12 months | $6.34 | – |
| Dividend growth a year, past | +15.2%over 5 years | – |
| Buyback yield | 0.3% | – |
| Shareholder yield | 0.8% | – |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.27T) is about 2,470.9 times Zevra Therapeutics ($514M), at today's prices.
Since November 21, 2016, LLY's price moved +1,657.7% and ZVRA's -86.6%. With dividends: LLY +1,944.6% (+35.2% a year), ZVRA -86.6% (-18.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for Zevra Therapeutics. Over the last twelve months they paid $6.34 and – per share.
At today's price, the P/E is 46.1 for LLY and 6.7 for ZVRA. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and 52.8% for Zevra Therapeutics, and the operating margin – and 60.8%. Revenue was $86.5B and $148M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.